Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to $4.1 million.

  • Iradimed's Accumulated Expenses rose 2396.15% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year increase of 2396.15%. This contributed to the annual value of $3.8 million for FY2024, which is 3591.41% up from last year.
  • Per Iradimed's latest filing, its Accumulated Expenses stood at $4.1 million for Q3 2025, which was up 2396.15% from $3.2 million recorded in Q2 2025.
  • In the past 5 years, Iradimed's Accumulated Expenses ranged from a high of $4.1 million in Q3 2025 and a low of $1.2 million during Q1 2021
  • For the 5-year period, Iradimed's Accumulated Expenses averaged around $2.6 million, with its median value being $2.3 million (2022).
  • Data for Iradimed's Accumulated Expenses shows a peak YoY increase of 6413.51% (in 2021) and a maximum YoY decrease of 2406.67% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Iradimed's Accumulated Expenses stood at $2.8 million in 2021, then grew by 2.04% to $2.9 million in 2022, then fell by 3.37% to $2.8 million in 2023, then soared by 35.91% to $3.8 million in 2024, then increased by 7.94% to $4.1 million in 2025.
  • Its last three reported values are $4.1 million in Q3 2025, $3.2 million for Q2 2025, and $2.3 million during Q1 2025.